Most pharmaceutical formulations also include a certain amount of lubricant to improve their fl owability and prevent their adhesion to the surfaces of processing equipment. Magnesium stearate is an additive that is most frequently used as a lubricant. Magnesium stearate is capable of forming fi lms on other tablet excipients during prolonged mixing, leading to a prolonged drug liberation time, a decrease in hardness, and an increase in disintegration time. It is hydrophobic, and there are many reports in the literature concerning its adverse eff ect on dissolution rates. Th e objective of this study was to evaluate the eff ects of two diff erent concentrations of magnesium stearate on dissolution properties of ranitidine hydrochloride coated tablet formulations labeled to contain  mg. Th e uniformity content was also checked. During the drug formulation development, several samples were designed for choice of the formulation. For this study, two formulations containing , and , of magnesium stearate added in the manufacture of cores were chosen. Fraction of ranitidine hydrochloride released in dissolution medium was calculated from calibration curves. Th e data were analyzed using pharmacopeial test for similarity of dissolution profi les ( f  equation), previously proposed by Moore and Flanner. Application of f  equation showed diff erences in time-course of ranitidine hydrochloride dissolution properties. Th e obtained values indicate diff erences in drug release from analyzed ranitidine hydrochloride formulations and could cause diff erences in therapeutic response.
Introduction
Lubrication is a process of high importance in the pharmaceutical industry. Lubricants are added to tablet formulations for two reasons: (a) to prevent adhesion of granules to the tooling-anti-adherent; (b) to improve granule fl ow properties-glidant. As anti-adherents, they reduce the friction between the wall and granules as the tablet is formed and ejected (,) . As glidants, they can enhance the blending of the active components and decrease processing problems and weight variability during compaction () . Th ere are numerous examples of the eff ects of lubrication on densifi cation and compactability of mixtures (, , ,) and also on tablet properties such as tensile strength, friability, disintegration (, ) . Among lubricants, magnesium stearate is the most widely used one. Commonly used concentrations range between ,- () . It appears in diff erent crystal forms, shows diff erent particle size and shape, and occurs in several hydrate forms (,,) . Its lubricating effectiveness was described by Delacourte et al. () . Magnesium stearate is capable of forming fi lms on other tablet excipients during prolonged mixing, leading to a prolonged drug liberation time, a decrease in hardness, and an increase in disintegration time. It is hydrophobic, and there are many reports in the literature concerning its adverse eff ect on dissolution rates. A tablet is compressed using high forces to form a solid compact of relatively low porosity, which enables it to endure subsequent handling (, ) . Drug absorption from solid dosage forms after oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the fi rst two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance () . Th e dissolution test facilitates assessment of the dissolution properties of the drug itself and thereby selection of the most appropriate excipients as well as optimization of proportions among them that result in the desired drug release behavior (,) . Th e objective of this study was to evaluate the eff ects of two diff erent concentrations of magnesium stearate on dissolution properties of ranitidine hydrochloride coated tablet formulations labeled to contain  mg. The uniformity content was also checked. Ranitidine hydrochloride is a histamine H-receptor antagonist. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal refl ux disease, and erosive esophagitis. During the drug formulation development, several samples were designed for choice of the formulation. For this study, two formulations containing , and , of magnesium stearate added in the manufacture of cores were chosen.
Materials and Methods
Reagents Th e used reagents were all of analytical grade, unless otherwise stated. Ranitidine hydrochloride working standard, hydrochloric acid, ammonium acetate, acetonitrile were provided by Merck (Darmstadt, Germany).
Tablet ingredients
For the tablet formulations the following ingredients were used and provided by different producers: ranitidine hydrochloride, titan dioxide (Merck Darmstadt, Germany), magnesium stearate and ethanol (Riedel-de Haën, Seelze-Hanover, Germany), microcrystalline cellulose, macrogol  (Fluka, Buchs, Switzerland), maize starch, povidone, hydroxypropyl cellulose (Sigma-Aldrich, Steinheim, Germany).
Tablet preparation
The process started with wet granulation where ranitidine hydrochloride, maize starch and povidone were mixed and granulated with ethanol. Th e granulation was dried to the prescribed moisture content and sieved. Sieved magnesium stearate was added. This mixture was homogenized and compressed into cores. For the process of fi lm coating, a homogenous dispersion (hydroxypropyl cellulose, titan dioxide, macrogol , ethanol) was prepared and sprayed onto cores. Both formulations ("A" and "B") were prepared under the same technological conditions. The only difference between them was the content of magnesium stearate added; , and , respectively. Preparation of standard solutions A standard curve of absorbance versus concentration was constructed using solutions of ranitidine hydrochloride in the dissolution medium (artificial gastric juice, pH=,; without pepsine, previously degasifi ed) ranging in concentration from , to , mg/ ml. Absorbance versus concentration plot was linear over this concentration range and was used to determine percent of drug dissolved in the dissolution experiments. UV absorbance of each standard solution was measured spectrophotometrically at  nm.
Dissolution test conditions and analysis procedure
The dissolution tests of ranitidine hydrochloride coated tablets (n=) were performed using USP apparatus  (n=), Van Kel VK  dissolution tester, at a stirring speed of  rpm (Van Kel, Cary, NC, ALIJA UZUNOVIĆ, EDINA VRANIĆ: EFFECT OF MAGNESIUM STEARATE CONCENTRATION ON DISSOLUTION PROPERTIES OF RANITIDINE HYDROCHLORIDE COATED TABLETS USA). The dissolution apparatus was maintained at °C throughout the experiment. Samples in the amount of  ml were withdrawn at  min intervals ( th ,  th and  th min). Prior to use, the dissolution media were equilibrated at oC overnight to deaerate the medium so that bubble formation during the test, due to escape of dissolved gases, was minimized. Dissolution samples were collected for analysis and replaced with an equal volume of fresh dissolution fl uid to maintain a constant total volume. Th ese samples were filtered using a , μm membrane filter (Sartorious GmbH, Goettingen, Germany). The dissolution apparatus was connected with UV/VIS spectrophotometer Shimadzu  (Shimadzu, Kyoto, Japan). Determination of dissolution rates for the active ingredient in film tablets is carried out by the previously mentioned spectrophotometric method. All dissolution tests were performed in triplicate.
Applied method to compare dissolution profi les
In this study, model independent approach that compare the dissolution profiles of a pair of drug products were applied to the dissolution data. The data were analyzed using pharmacopeial test for similarity of dissolution profiles (f  equation), previously proposed by Moore and Flanner () . Th is similarity factor has been adopted by the Center for Drug Evaluation and Research (FDA) and by Human Medicines Evaluation Unit of Th e European Agency for the Evaluation of Medicinal Products (EMEA), as a criterion for the assessment of the similarity between two in vitro dissolution profi les and is included in the "Guidance on Immediate Release Solid Oral Dosage Forms; Scaleup and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing; In Vivo Bioequivalence Documentation" () , commonly called SUPAC IR, and in the "Note For Guidance on Quality of Modifi ed Release Products: A. Oral Dosage Forms; B. Transdermal Dosage Forms; Section I (Quality)" () . The similarity factor (f  ) as defined by FDA and EMEA is a logarithmic reciprocal square root transformation of one plus the mean squared (the average sum of squares) differences of drug percent dissolved between the test and the reference products:
where n is the number of dissolution time points, R t is the reference assay at time point t.
Content uniformity testing
The following experiment examined the content uniformity of the active ingredient in tablets and was carried out by high-performance liquid chromatography (HPLC) method. Th e system consisted of a pump, injection valve, autosampler and variable wavelength detector (Shimadzu, Kyoto, Japan). Th e mobile phase consisted of (:, v/v) mixture of , mol/l ammonium acetate solution and acetonitrile. Th e fl ow rate was , ml/min, the injection volume  μl, the column temperature oC and the detection wavelength  nm. LiChrospher RP column (mm×,mm×μm) was used throughout the experiments. Under the abovementioned conditions, the retention time of the analyte was ca.  min.
Results and Discussion
The results of dissolution studies are summarized in Table , Table  and Figure  , which show the fraction of the dissolved drug as a function of time. According to the USP () , in vitro release of ranitidine hydrochloride coated tablets fulfi lled all requirements if the dissolution of each of the six coated tablets was not less than  of the declared contents for a period of  minutes. In our study, in vitro release of ranitidine hydrochloride from both formulations fulfi lled these requirements and exhibited release profile: , and ,, for "A" and "B" formulation. Fractions of ranitidine hydrochloride released in dissolution medium were calculated from calibration curves. The data were analyzed using pharmacopeial test for similarity of dissolution profiles (f  equation), previously proposed by Moore and Flanner. The f  value between  and  suggests that the dissolution profi les are similar. Th e value of  suggests that the test and reference dissolution profiles are identical. Th e smaller the value, the larger the dissimilarity between dissolution profi les. Fractions of the released ranitidine hydrochloride were compared using this value. After interpolating data for dissolution profi les for "A" and "B" formulation we obtained value f  = ,. This value indicates differences in drug release from analyzed ranitidine hydrochloride coated tablets. We can hypothesize that magnesium stearate added in "B" formulation (concentration ,), being hydrophobic in nature, forms a stronger fi lm at the surface of other excipients or the API (ranitidine hydrochloride). In that manner, it enables the dissolution medium to remain on the surface of the particle causing slower wettabilty, and dissolution rate as well. Determination of the content uniformity of ranitidine in our formulations was carried out by HPLC method. Th e procedure was performed on ten tablets separately. According to the USP (), the content uniformity of ranitidine expressed as  of the declared content should be within the limits of - and relative standard deviation (R.S.D.) should be equal or smaller than . The results of content uniformity studies are summarized in Table  and Table  The results of the content uniformity analysis of our tablet formulations were , ±, and ,±, for formulation A and B, respectively, which fulfills pharmacopoeial requirements. 
Conclusion
◊ According to the results obtained in this study, we can conclude that our "A" and "B" formulations satisfi ed pharmacopeial requirements concerning dissolution rate and content uniformity. ◊ Application of f  equation shows diff erences in time-course of ranitidine hydrochloride dissolution, and indicates change in dissolution properties. With the advent of international harmonization of scientifi c protocols and implementation of SUPAC guidelines including site-to site manufacturing conditions, such changes have important regulatory implications. ◊ Th e obtained values indicate diff erences in drug release from analyzed ranitidine hydrochloride formulations and may cause diff erences in therapeutic response. ◊ We can hypothesize that magnesium stearate added in "B" formulation (concentration ,), being hydrophobic in nature, forms a stronger fi lm at the surface of other excipients or the API (ranitidine hydrochloride). In that manner, it enables the dissolution medium to remain on the surface of the particle causing slower wettabilty as well as dissolution rate. ◊ Application of f  equation showed diff erences in time-course of ranitidine hydrochloride dissolution. With the advent of international harmonization of scientifi c protocols and implementation of SUPAC guidelines including site-to site manufacturing conditions, such process comparisons have important regulatory implications. ◊ However, more data on in vivo drug absorption profi les will provide additional information needed to complete profi le characterization of the investigated formulations.
